Suppr超能文献

在意向性分析中进行治疗转换的非劣效性试验的功效和样本量计算,比较受限平均生存时间。

Power and sample size calculation for non-inferiority trials with treatment switching in intention-to-treat analysis comparing RMSTs.

作者信息

Shih Austin, Hsu Chih-Yuan, Shyr Yu

机构信息

Department of Mathematics, Vanderbilt University, Nashville, TN, USA.

Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.

出版信息

Res Sq. 2024 Dec 12:rs.3.rs-5418253. doi: 10.21203/rs.3.rs-5418253/v1.

Abstract

BACKGROUND

Difference in Restricted Mean Survival Time (DRMST) has attracted attention and is increasingly used in non-inferiority (NI) trials because of its superior power in detecting treatment effects compared to hazard ratio. However, when treatment switching (also known as crossover) occurs, the widely used intention-to-treat (ITT) analysis can underpower or overpower NI trials.

METHODS

We propose a simulation-based approach, named , to calculate powers and determine the necessary sample size to achieve a desired power for non-inferiority trials that allow treatment switching, in ITT analysis using DRMST.

RESULTS

Real-world and simulated examples are used to illustrate the proposed method and examine how switching probability, switching time, the relative effectiveness of treatments, allocation ratio, and even time distribution influence powers and sample sizes. Our simulation study shows that switching time and switching probability decrease or increase powers and sample sizes compared to those in the scenarios without treatment switching. A shorter switching time and a higher switching probability amplify the magnitude of these changes. The direction of the change in powers and sample sizes depends on the relative effectiveness of the treatments. When , power decreases and sample size increases, while leads to the opposite effect, where and are the median survivals in the control and experimental groups, respectively.

CONCLUSIONS

This simulation-based approach offers a preview of how treatment switching can influence powers and sample sizes in NI trials, providing investigators with useful information before conducting the trials. is freely available at https://github.com/cyhsuTN/nifts.

摘要

背景

受限平均生存时间差异(DRMST)已引起关注,并且由于其在检测治疗效果方面比风险比具有更强的功效,因此越来越多地用于非劣效性(NI)试验。然而,当发生治疗转换(也称为交叉)时,广泛使用的意向性分析(ITT)可能会使NI试验的功效不足或功效过强。

方法

我们提出了一种基于模拟的方法,名为 ,用于在使用DRMST的ITT分析中,计算允许治疗转换的非劣效性试验的功效,并确定达到所需功效所需的样本量。

结果

使用实际案例和模拟示例来说明所提出的方法,并研究转换概率、转换时间、治疗的相对有效性、分配比例以及时间分布如何影响功效和样本量。我们的模拟研究表明,与没有治疗转换的情况相比,转换时间和转换概率会降低或增加功效和样本量。较短的转换时间和较高的转换概率会放大这些变化的幅度。功效和样本量变化的方向取决于治疗的相对有效性。当 时,功效降低而样本量增加,而 则会产生相反的效果,其中 和 分别是对照组和实验组的中位生存期。

结论

这种基于模拟的方法提供了治疗转换如何影响NI试验的功效和样本量的预览,在进行试验之前为研究人员提供有用的信息。 可在https://github.com/cyhsuTN/nifts上免费获取。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4a89/11661365/231d8c35d5f9/nihpp-rs5418253v1-f0001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验